Search company, investor...

Stage

Unattributed | Alive

Total Raised

$2.57M

Last Raised

$150K | 11 yrs ago

About Revelation

Revelation is a provider of Immersive Research. The company's custom and turnkey software and solutions empower marketing research professionals to study consumers in the moment. Revelation leverages social web philosophy and technology to provide customer-centric tools and methodologies. With these easy-to-use capabilities, researchers can practically envision participant experiences through behaviors, environment and emotions. They can then leverage these experiences to make smart business decisions.

Headquarters Location

1200 NW Naito Parkway Suite 630

Portland, Oregon, 97709,

United States

Loading...

Loading...

Revelation Patents

Revelation has filed 9 patents.

The 3 most popular patent topics include:

  • orthopedic surgical procedures
  • drilling technology
  • implants (medicine)
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/11/2021

10/31/2023

Drilling technology, Implants (medicine), Orthopedic surgical procedures, Hole making, Metalworking cutting tools

Grant

Application Date

5/11/2021

Grant Date

10/31/2023

Title

Related Topics

Drilling technology, Implants (medicine), Orthopedic surgical procedures, Hole making, Metalworking cutting tools

Status

Grant

Latest Revelation News

Revelation Biosciences Inc. Receives Approval to Start a Phase 1 Clinical Study of REVTx-99 an Experimental Treatment for COVID-19

Oct 1, 2020

October 01, 2020 09:00 AM Eastern Daylight Time MENLO PARK, Calif.--( BUSINESS WIRE )--Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today that it has been granted approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to conduct a Phase 1 clinical study of REVTx-99 in healthy volunteers (RVL-HV01 study). HREC approval permitted Revelation to complete the required Clinical Trial Notification to the Therapeutic Goods Administration. REVTx-99 is in development as an early treatment for SARS-CoV-2 Infection (COVID-19). RVL-HV01 is a single site, placebo-controlled, single dose, escalating dose study to determine the safety and tolerability of intranasal REVTx-99 in healthy adult volunteers. The study is expected to begin enrolling participants in Q4 2020. "We are excited to announce the initiation of clinical development for REVTx-99, our first pipeline candidate to enter Phase 1 clinical study," said James Rolke, Chief Executive Officer of Revelation. “Due to the severity and high hospitalization rate of SARS-CoV-2 infection and the urgent need for effective treatments, we are looking forward to embarking on clinical development and rapidly advancing this therapeutic candidate.” RVL-HV01 will enroll up to 32 participants in 4 cohorts. The primary endpoints are to determine the safety and tolerability of escalating intranasal doses of REVTx-99 in healthy adult volunteers and to determine the pharmacodynamic effect of REVTx-99 in healthy adult volunteers as measured by nasal and systemic cytokine levels throughout the course of treatment. There are multiple exploratory pharmacodynamic endpoints. Revelation expects enrollment of RVL-HV01 to begin during the fourth quarter of 2020, with topline data early in the first quarter of 2021. After completion of this study, Revelation plans to initiate a Phase 2 study during the first half of 2021 in early stage COVID-19 patients at risk for hospitalization. For more information on Revelation, please visit www.RevBiosciences.com . About REVTx-99 REVTx-99 is a proprietary intranasal formulation of phosphorylated hexaacylated disaccharide or PHAD®, a synthetic version of monophosphoryl lipid A. SARS-CoV-2 viral proteins have been shown to block the production of interferons, a key part of the innate immune response to viral infection, resulting in worse outcomes. REVTx-99 acts by stimulating the innate immune response via interaction with toll-like receptor 4 (TLR4) and activation of the TIR-domain-containing adapter-inducing interferon-β (TRIF) pathway to produce protective cytokines including Type I and Type II interferons. The innate immune system is the first line of defense against invading pathogens such as bacteria and viruses. Toll-like receptors (TLRs) are associated with sentinel cells (e.g. macrophages, dendritic cells) and serve a vital role in the innate immune system response. TLRs recognize repeated molecular patterns associated with pathogens (PAMPS). When a pathogen invades a subject, TLRs recognize PAMPS as foreign and activate the innate immune response, inducing the production of numerous cytokines to combat the invading pathogen and stimulate the adaptive immune response. About Revelation Biosciences Inc. Revelation Biosciences Inc., is a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. The Company has several product candidates in development. REVTx‑99, the lead therapeutic candidate, is an intranasal immunomodulator for the early treatment of SARS-CoV-2 infection. An expansion of REVTx‑99 therapeutic indications is planned targeting early treatment and prevention of respiratory viral infection such as with influenza A or B, parainfluenza, and respiratory syncytial virus. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to the Company’s therapeutic pipeline, Revelation is also developing REVDx-501, a rapid point of care diagnostic that can be used to detect any respiratory viral infection regardless of virus type without the need for specialized instrumentation. For more information on Revelation, please visit www.RevBiosciences.com . Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. These risks include, but are not limited to, risks relating to: the timing for the filing of an Investigational New Drug Application; the timing, costs, conduct and outcome of RVL-HV01; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for REVTx-99 and expanded indications, REVTx-200, REVDx-501, or any other product candidates; potential indications for which our product candidates may be developed; the potential impact that COVID-19 may have on us, our suppliers, vendors, regulatory agencies, our employees and the global economy as a whole; and the expected duration over which the Company’s balance will fund us. Contacts

Revelation Frequently Asked Questions (FAQ)

  • Where is Revelation's headquarters?

    Revelation's headquarters is located at 1200 NW Naito Parkway, Portland.

  • What is Revelation's latest funding round?

    Revelation's latest funding round is Unattributed.

  • How much did Revelation raise?

    Revelation raised a total of $2.57M.

  • Who are the investors of Revelation?

    Investors of Revelation include Oregon Venture Fund and University of Central Florida Business Incubation Program.

  • Who are Revelation's competitors?

    Competitors of Revelation include Neurons and 4 more.

Loading...

Compare Revelation to Competitors

Logica Research Logo
Logica Research

Logica Research, formerly known as Koski Research, provides marketing research solutions for business-related queries. It offers insight on product development, service enhancements, and communications that improve people’s financial lives, deepen brand engagement, and drive business growth. Logica Research's clients include financial institutions, growing financial services, and fintech companies. It is based in San Francisco, California.

Kantar Logo
Kantar

Kantar is a data investment management company. The company offers research, insight, information, and consultancy services. It enables companies to offer clients business insights at every point of the consumer cycle. Kantar was founded in 1993 and is based in London, U.K.

Toluna Logo
Toluna

Toluna provides a consumer intelligence platform for the finance, automotive, education, retail, and healthcare industries. It offers an online market research technology suite to create surveys, manage panels and build online communities, providing market research organizations and agencies with insights into the on-demand economy. The company was founded in 2000 and is based in Norwalk, Connecticut.

Attention Insight Logo
Attention Insight

Attention Insight is a company that focuses on providing AI-driven pre-launch analytics in the technology sector. The company offers a service that uses predictive attention heatmaps to provide insights on how consumers will engage with various concepts such as landing pages, advertisements, and packaging before they are launched. This service primarily caters to the ecommerce industry, helping businesses optimize their designs and drive higher conversions. It was founded in 2019 and is based in Vilnius, Lithuania.

Alpha.One Logo
Alpha.One

Alpha.One is a company that focuses on neuromarketing and artificial intelligence in the marketing industry. The company offers AI and consumer neuroscience solutions that help predict consumer behavior and improve the effectiveness of creative content. Their main products include an AI tool that predicts the outcome of eye tracking research studies and a creative insights platform for YouTube ads. It is based in Rotterdam, Netherlands.

Expoze.io Logo
Expoze.io

Expoze.io is a company that operates in the technology sector, with a focus on artificial intelligence and data science. The company offers a platform that uses AI to predict visual attention on images and videos, essentially functioning as an online attention prediction tool. This service is primarily used by professionals in marketing, UX/UI design, and conversion rate optimization. It was founded in 2019 and is based in Rotterdam, Netherlands.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.